Cerus (CERS +70%) soars after Swiss regulators approve its Intercept blood system, which...

|About: Cerus Corporation (CERS)|By:, SA News Editor

Cerus (CERS +70%) soars after Swiss regulators approve its Intercept blood system, which lengthens platelets' shelf life by two days to a week by inactivating blood-borne pathogens. Drug is not yet available in U.S.